Berges-Gimeno M Pilar, Simon Ronald A, Stevenson Donald D
Scripps Clinic, La Jolla, California 92037, USA.
Ann Allergy Asthma Immunol. 2002 Nov;89(5):474-8. doi: 10.1016/S1081-1206(10)62084-4.
Aspirin-exacerbated respiratory disease (AERD) is a clinical syndrome characterized by chronic rhinitis, nasal polyps, asthma, and precipitation of asthma and rhinitis attacks after ingestion of aspirin (ASA) and most nonsteroidal anti-inflammatory drugs (NSAIDs). Most information about the disease in the United States has come from small samples of patients.
The purpose of this study was to examine the natural history and clinical characteristics of 300 AERD patients, referred to our institution for aspirin desensitization.
All potential AERD patients were evaluated using a standard questionnaire that included information about clinical characteristics and natural progression of their disease, previous history of reactions to ASA and other NSAIDs, current use of medications, and ethnic backgrounds. All patients underwent oral ASA challenges to prove they had AERD.
From patients' history we found that the average age at onset of AERD was 34 years, and that 57% were female. Counting ASA as an NSAID, 33% had previously reacted on two occasions to NSAIDs and 36% on more than three occasions to NSAIDs, whereas only 27% had reacted to one NSAID before they came to us for evaluation. Our patients had averaged 5.5 episodes of sinusitis per year. There were no significant differences in the clinical characteristics or use of medications between genders. Ethnicity was heterogeneous in most participants.
AERD begins in the third decade of life and in both sexes. The disease progressed over the 13 years between historical onset and current evaluation, with more sinusitis and need for controller medications over time. There was no ethnic or familial distribution of AERD.
阿司匹林诱发的呼吸道疾病(AERD)是一种临床综合征,其特征为慢性鼻炎、鼻息肉、哮喘,以及在摄入阿司匹林(ASA)和大多数非甾体抗炎药(NSAIDs)后诱发哮喘和鼻炎发作。在美国,关于该疾病的大多数信息来自对少量患者的研究。
本研究旨在探讨300例因阿司匹林脱敏而转诊至我院的AERD患者的自然病史和临床特征。
所有疑似AERD患者均使用标准问卷进行评估,问卷内容包括疾病的临床特征和自然进展、既往对ASA和其他NSAIDs的反应史、当前用药情况以及种族背景。所有患者均接受口服ASA激发试验以确诊AERD。
从患者病史中我们发现,AERD的平均发病年龄为34岁,57%为女性。若将ASA视为NSAID,33%的患者既往曾两次对NSAIDs产生反应,36%的患者曾三次以上对NSAIDs产生反应,而在前来我院评估之前,只有27%的患者曾对一种NSAID产生反应。我们的患者每年平均发生5.5次鼻窦炎。男女在临床特征或用药方面无显著差异。大多数参与者的种族构成较为多样。
AERD在30岁左右发病,男女均可患病。从发病到当前评估的13年间,疾病不断进展,鼻窦炎发作次数增多,对控制药物的需求也增加。AERD不存在种族或家族分布特征。